Description
Alnylam Pharmaceuticals: Launch & Uptake of Vutrisiran
Alnylam Pharmaceuticals delivered a robust performance in the second quarter of 2024, marked by significant growth in global net product revenues which totaled $410 million, recording a year-over-year increase of 34%. This growth was predominantly driven by a 37% increase in the hereditary ATTR amyloidosis (hATTR) franchise. Given this strong performance, the company has updated its revenue guidance for the year, increasing it by 11% at the midpoint.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
